Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Semagacestat

Generic Name: Semagacestat

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₇N_₃O_₄

CAS Number: 425386-60-3

Unique Ingredient Identifier: 3YN0602W4W

Overview

Semagacestat has been used in trials studying the treatment of Alzheimer Disease.

Background

Semagacestat has been used in trials studying the treatment of Alzheimer Disease.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Semagacestat for Alzheimer's Patients

Phase 3

Completed

Posted: 2009/12/18

Sponsor:Eli Lilly and Compan...

ID:NCT01035138

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

Phase 1

Completed

Posted: 2008/10/02

Sponsor:Eli Lilly and Compan...

ID:NCT00765115

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

Phase 3

Completed

Posted: 2008/09/30

Sponsor:Eli Lilly and Compan...

ID:NCT00762411

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

Phase 3

Completed

Posted: 2008/01/15

Sponsor:Eli Lilly and Compan...

ID:NCT00594568

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

AstraZeneca and Lilly Form $500M Alliance to Develop Novel BACE Inhibitor for Alzheimer's Disease

3 months ago

AstraZeneca and Eli Lilly have formed a strategic partnership to develop AZD3293, a promising oral BACE inhibitor for early Alzheimer's disease, with Lilly contributing $500 million in milestone payments.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy